research use only
Cat.No.S4728
| Related Targets | Adrenergic Receptor Estrogen/progestogen Receptor GPR Glucocorticoid Receptor ACE RAAS Progesterone Receptor Opioid Receptor PGES THR |
|---|---|
| Other Androgen Receptor Inhibitors | Bavdegalutamide (ARV-110) RU58841 EPI-001 Galeterone Cyproterone Acetate Ailanthone Proxalutamide (GT0918) GSK-2881078 Chlormadinone acetate GDC-2992 |
|
In vitro |
DMSO
: 49 mg/mL
(198.93 mM)
Ethanol : 18 mg/mL Water : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 246.31 | Formula | C17H14N2 |
Storage (From the date of receipt) | |
|---|---|---|---|---|---|
| CAS No. | 1968-05-4 | Download SDF | Storage of Stock Solutions |
|
|
| Synonyms | DIM | Smiles | C1=CC=C2C(=C1)C(=CN2)CC3=CNC4=CC=CC=C43 | ||
| Targets/IC50/Ki |
Androgen Receptor
|
|---|---|
| In vitro |
DIM is a potent radioprotector and mitigator that functions by stimulating an ATM-driven DDR-like response and NF-κB survival signaling. This compound can inhibit invasion, angiogenesis, and proliferation and induce apoptosis in tumor cells by modulating signaling pathways involving AKT, NF-κB, and FOXO3. It can also inhibit estrogen-inducible gene expression and cause an endoplasmic reticulum stress response. This chemical alters estrogen metabolism by shifting metabolism from carcinogenic 16α-hydroxy to inert 2-hydroxy derivatives, and it antagonizes estrogen and androgen receptor activity.
|
| In vivo |
Preliminary studies show this compound is most effective against total body irradiation (TBI) when given in multiple once-daily doses. Treatment of DIM has radioprotection and mitigation properties in vivo. This chemical activates ATM in normal tissues. It can be given to mice (250 mg/kg) by oral gavage, with no acute toxicity and excellent bioavailability.
|
References |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.